Spotlight On... J&J, AbbVie swell Imbruvica patient pool with first-line FDA nod in CLL; Advair safety profile comparable to Flonase's, GSK says; Jimmy Carter doesn't need melanoma treatment after Merck's Keytruda; and more...

AbbVie ($ABBV) has said it expects nearly a third of Imbruvica's future growth to come from moving into earlier lines of therapy in the drug's approved indications. And Friday, the therapy did just that, snagging a first-line go-ahead from the FDA in patients with chronic lymphocytic leukemia (CLL). More from FiercePharma

> Amid a shortage of doctors and a tide of new patients with insurance under the Affordable Care Act, an increasing number of states are granting physician assistants more autonomy. Report

> Study data published in the New England Journal of Medicine shows Advair's safety profile is comparable to that of Flonase, GlaxoSmithKline ($GSK) says. Release

> Royalty Pharma has purchased UCLA's royalty rights connected with prostate cancer pill Xtandi. Release

> The FDA has approved CSL Behring's Idelvion, a hemophilia B therapy with dosing intervals of up to two weeks. Release

 > GSK says it has confirmed the safety profile of respiratory med Nucala with a long-term study that showed similar results to previous trials. Release

And Finally... U.S. President Jimmy Carter says he'll no longer need treatment for melanoma after receiving Merck ($MRK) immunotherapy Keytruda. Report

Suggested Articles

An oncologist leader RBC Capital Markets interviewed expressed comfort that Trodelvy will succeed in earlier-line TNBC and in HR-positive disease.

COVID-19 vaccine makers' recent safety pledge continues to increase positive sentiment among Americans, new Harris Poll data say.

Rather than accept a filing based on phase 1/2 data, the FDA wants Novartis to run a phase 3 for a market-expanding version of gene therapy Zolgensma.